Conference urges further consultation on NICE diabetes guidanceBMJ 2015; 350 doi: https://doi.org/10.1136/bmj.h3203 (Published 11 June 2015) Cite this as: BMJ 2015;350:h3203
- Nigel Hawkes
Draft guidelines issued by the National Institute for Health and Care Excellence (NICE) for the treatment of type 2 diabetes are a recipe for failure, a Westminster Health Forum seminar was told on 10 June.
The draft guidelines included drugs that should not be offered routinely, they excluded others that NICE has previously found to be cost effective, and they prescribed an overly rigid sequence rather than allowing treatment to be tailored to individual cases, said Lisa Anson, president of AstraZeneca UK/Ireland. After widespread criticism of the draft guidance NICE has said that substantial changes have been made, but Anson pleaded for the revised version to be made the subject of renewed consultation to make sure …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial